6th Annual Pharma R&D Asia Congress

Over 170 senior-level decision makers in Research and Development, Drug Discovery, in Licensing, Biomarkers and Clinical Development  from local and multinational pharma and biotech companies in China, South Korea, Japan, India and China

Over 40 presentations, case studies and panel discussions delivered by leading biotech companies, global pharma organisations & internationally renowned academic institutions

Do not miss out on the main themes of the event in 2016:

  • Regulatory updates in the China and impact on multinational drug development activities
  • Innovation strategies to advance R&D in Asia
  • Overcoming challenges in developing a global regulatory strategy
  • Types of R&D-CRO collaboration& business models
  • Enabling technologies and novel methods in drug development, implementing Biomarkers, biometrics, data management and developing diagnostics

Co-located with the 5th Annual Clinical Development and Trials Asia Congress

14 prescheduled one to one meetings, exhibition spaces and informal networking opportunities

Oxford Global Conferences are proud to present the 6th Annual Pharma R&D World Asia Congress and co-located 5th Annual Clinical Development and Trials Asia Congress to be held in January 2016 in Shanghai, China.

Attended by over 170 industry leaders, the 6th Annual Pharma R&D World Asia Congress will consist of case studies in novel scientific innovations in Discovery and Development in Asia.

The dynamics of outsourcing has changed dramatically over these few years, and CROs are emerging as strategic drug development partners. Key global collaboration projects, changes in the model of CRO outsourcing & partnering strategies are discussed here, along with how pharm companies adapt to changes in regulation policies and optimise in licensing opportunities.

On Day Two, our esteemed experts will cover strategies to accelerate drug development timelines. The topics include the latest drug innovation and development activities in improving productivity in Asia.

Do not miss out on the VP and executives interactive panel discussions featured prominently on the programme, where key stakeholders interact, debate and discuss the most pertinent issues in the Drug and Clinical development and pharma R&D innovation.

  • PANEL 1: Will Asia “Produce” in Regards to Drug Development
  • PANEL 2: Regulatory updates for Registration for Multinational Clinical Trials – China, Japan, South Korea & Singapore
  • PANEL 3: Innovation Strategies to Advance R&D in Asia
  • PANEL 4: CRO – R&D Collaborations and Business Models

The co-located 5th Annual Clinical Development and Trials Asia Congress will offer invaluable insights into the changing regulatory environment in China and surrounding regions and cover successful strategies and innovative technologies in enabling clinical development and clinical trial management.

On Day One, hear from senior speakers covering key discussions on the changing regulatory environment in China and impact of this on multinational drug development activities, as well as updates on registration for multinational clinical trials.  Also, do not miss out on optimising clinical development strategies in oncology and other therapeutic areas from China, Japan, South Korea, India, & Singapore.

There is a featured enabling technologies stream on day one, dedicated to managing Clinical Development, implementing Biomarkers into clinical research and developing diagnostics for Clinical Trials.

On Day Two, the innovative programme will cover the key operational, logistical, and regulatory aspects of conducting clinical trials in China and other Asian countries. It will focus on Clinical Trial Management strategies for minimising costs, managing supply chain, CRO partnerships in accelerating clinical trial timelines and bridging studies in Asia for Global Development.

Other events in this Series

3rd Biosimilars Asia Congress, 22nd & 23rd  September 2015


Clinical Trials & Outsourcing Asia and Pharma R&D Asia 2015 Sponsors:



Media Partners